Company Overview - Scholar Rock is a biotech company celebrating its 15th anniversary in 2023, founded in 2012 with innovative technology from Tim Springer and Len Zon's lab [2] - The company focuses on developing antibody technology to inhibit difficult-to-target growth factors and proteins in the body [2] Key Achievements - Scholar Rock's most significant success has been the inhibition of myostatin, leading to the first positive pivotal trial targeting myostatin after three decades of attempts by the pharma and biotech industries [3] - The trial results were reported at the end of 2024, and the company is currently awaiting FDA and EMA approval for the product launch this year [3]